PNC-27 (PNC-27 (p53-Derived Anticancer Peptide))
An experimental peptide derived from the p53 tumor suppressor protein, studied for selectively destroying cancer cells. It remains preclinical and is included for educational reference; it is not an approved therapy.
How it works
Contains a p53 domain fused to a membrane-penetrating sequence. It is proposed to bind HDM-2 that is preferentially expressed on cancer cell membranes, forming pores that cause selective necrosis of cancer cells while reportedly sparing normal cells in studies.
Key facts
- Molecular weight: ~3.2 kDa
- Half-life: Short (peptide)
- Bioavailability: Injection (research)
- Storage: Lyophilized: -20°C (research material).
Dosing overview
- Typical dose: Not established for humans
- Frequency: Research only
- Duration: Research only
- Route: Injection (research)
Protocol notes
- No validated human dosing exists; all use is experimental and unapproved.
- Animal and cell studies used research-specific dosing regimens.
- Included for educational completeness, not as a cancer treatment.
Reported benefits
- Selective cancer-cell targeting (preclinical)
- p53/HDM-2 mechanism of interest
- Reported sparing of normal cells (studies)
Possible side effects
- Unknown human safety
- No approved human use
- Unproven efficacy in humans
Research
- PNC-27 selective cancer cell necrosis (2010): Reported to selectively induce necrosis of cancer cells via membrane HDM-2 binding while sparing normal cells in preclinical models.
Compare PNC-27
Research and educational reference only. Not medical advice.